Amarillo Biosciences (OTCMKTS:AMAR) Posts Quarterly Earnings Results

Amarillo Biosciences (OTCMKTS:AMAR) issued its earnings results on Monday, November 20th. The company reported ($0.01) EPS for the quarter, Bloomberg Earnings reports.

Amarillo Biosciences (OTCMKTS AMAR) remained flat at $$0.26 during trading hours on Thursday. 189 shares of the company’s stock traded hands, compared to its average volume of 2,066. Amarillo Biosciences has a 52 week low of $0.16 and a 52 week high of $0.30.

In other Amarillo Biosciences news, CEO Stephen T. Chen purchased 203,000 shares of the stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $0.19 per share, with a total value of $38,570.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 219,000 shares of company stock valued at $42,800 in the last three months.

WARNING: “Amarillo Biosciences (OTCMKTS:AMAR) Posts Quarterly Earnings Results” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/amarillo-biosciences-inc-amar-releases-quarterly-earnings-results-updated-updated.html.

About Amarillo Biosciences

Amarillo Biosciences, Inc is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form.

Receive News & Ratings for Amarillo Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply